Oncology
Metastatic Head and Neck Cancer
0
Pipeline Programs↗
6
Active Trials↗
6
Companies Involved↗
Metastatic Head and Neck Cancer is an early-stage landscape with 0 programs across 6 companies. The most active players are AstraZeneca, Novartis, CSPC ZhongQi Pharmaceutical Technology Co., Ltd..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
54
clinical trials
Completed36 · 67%
Terminated10 · 19%
Recruiting3 · 6%
Active, not recruiting2 · 4%
Unknown status1 · 2%
Not yet recruiting1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
54 trials
Pembrolizumab and Radiotherapy for Oligometastatic Head and Neck Cancer
Recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT05815927·200 enrolled
Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients
Active, not recruiting·—·Phase 2·NCT04414540·20 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)